MAYER, Jiří, Ivo PALÁSEK, Zdeněk POSPÍŠIL, Soňa ŠTRUNCOVÁ, Dana DVOŘÁKOVÁ, Marek BORSKÝ, Martin KLABUSAY, Michael DOUBEK, Yvona BRYCHTOVÁ a Zdeněk RÁČIL. Detection of molecular relapse of AML by very frequent quantitative monitoring of different molecular markers (Fusion transcripts and WTI) in different compartments (peripheral blood, bone marrow, and selected CD34+bone marrow cells) and its treatment... 2006. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{759107, author = {Mayer, Jiří and Palásek, Ivo and Pospíšil, Zdeněk and Štruncová, Soňa and Dvořáková, Dana and Borský, Marek and Klabusay, Martin and Doubek, Michael and Brychtová, Yvona and Ráčil, Zdeněk}, keywords = {AML; molecular relapse; peripheral blood; bone marrow}, language = {eng}, title = {Detection of molecular relapse of AML by very frequent quantitative monitoring of different molecular markers (Fusion transcripts and WTI) in different compartments (peripheral blood, bone marrow, and selected CD34+bone marrow cells) and its treatment...}, year = {2006} }
TY - CONF ID - 759107 AU - Mayer, Jiří - Palásek, Ivo - Pospíšil, Zdeněk - Štruncová, Soňa - Dvořáková, Dana - Borský, Marek - Klabusay, Martin - Doubek, Michael - Brychtová, Yvona - Ráčil, Zdeněk PY - 2006 TI - Detection of molecular relapse of AML by very frequent quantitative monitoring of different molecular markers (Fusion transcripts and WTI) in different compartments (peripheral blood, bone marrow, and selected CD34+bone marrow cells) and its treatment... KW - AML KW - molecular relapse KW - peripheral blood KW - bone marrow N2 - The paper deals with Detection of molecular relapse of AML by very frequent quantitative monitoring of different molecular markers (Fusion transcripts and WTI) in different compartments (peripheral blood, bone marrow, and selected CD34+bone marrow cells) and its treatment. ER -
MAYER, Jiří, Ivo PALÁSEK, Zdeněk POSPÍŠIL, Soňa ŠTRUNCOVÁ, Dana DVOŘÁKOVÁ, Marek BORSKÝ, Martin KLABUSAY, Michael DOUBEK, Yvona BRYCHTOVÁ a Zdeněk RÁČIL. \textit{Detection of molecular relapse of AML by very frequent quantitative monitoring of different molecular markers (Fusion transcripts and WTI) in different compartments (peripheral blood, bone marrow, and selected CD34+bone marrow cells) and its treatment...}. 2006.
|